Previous 10 | Next 10 |
home / stock / icotf / icotf news
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc . (TSXV: ICO) (OTCQB: ICOTF) (" iCo " or the " Company "), announces that they are submitting an application to the TSX Venture Exchange to amend the exercise price of 66,200,000 previously granted com...
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), iCo Therapeutics, Inc. ("iCo") and Skymount Medical, Inc. ("Skymount") announced today that they have entered into a non-binding Memorandum of Understanding...
iCo Therapeutics (ICOTF): Q3 Total comprehensive loss of C$0.2M.Cash and cash equivalents of C$0.17MPress Release For further details see: iCo Therapeutics reports Q3 results
Vancouver, British Columbia--(Newsfile Corp. - November 24, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended September 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and ...
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that two poster presentations regarding iCo's Oral Amphotericin B technology (...
iCo Therapeutics ( OTCQB:ICOTF ) : Q2 Net loss of C$0.34M. More news on: iCo Therapeutics Inc., Earnings news and commentary, Financial stocks news, , Read more ...
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended June 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented und...
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today the publication of results of their Oral Amphotericin B (iCo 019) Phase 1a Study ...
iCo Therapeutics ( OTCQB:ICOTF ) : Q1 net loss of C$0.65M More news on: iCo Therapeutics Inc., Earnings news and commentary, Financial stocks news, , Read more ...
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended March 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented unde...
News, Short Squeeze, Breakout and More Instantly...
Ico Therapeutics Inc Company Name:
ICOTF Stock Symbol:
OTCMKTS Market:
Ico Therapeutics Inc Website:
Tekumo Inc (BCNN) is expected to report for Q3 2023 Diamcor Mining Inc (DMIFF) is expected to report for Q2 2024 American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Northwest Biotherapeutics Inc (NWBO) is expected to report for Q1 2024 Inspired Entert...
Satellos Bioscience Inc Ordinary Shares (ICOTF) is expected to report for Q3 2023
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced that its wholly owned subsidiary, Amphotericin B Technologies, Inc., has entered into an agreement with IIT Research Institute to test the in ...